Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 4/2012

01.04.2012 | Original Article

The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia

verfasst von: Emma K. Hansson, Lena E. Friberg

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Chemotherapy-induced neutropenia is associated with the risk of developing febrile neutropenia (FN). The aim was to describe the time course of myelosuppression in breast cancer patients treated with docetaxel and to investigate how the shape of the predicted myelosuppression time course and earlier proposed risk factors influence the probability of developing FN.

Methods

Neutrophil counts from 140 breast cancer patients with observed grade IV neutropenia during the first course of docetaxel treatment were included. Twenty-six of the patients (19%) experienced FN. The myelosuppression time course was described using a semi-mechanistic myelosuppression model in NONMEM. The individual myelosuppression model parameters [baseline neutrophil count, mean transit time (MTT) and drug effect parameter (EC50)], myelosuppression descriptors (nadir, duration of grade IV neutropenia) and earlier suggested risk factors (age, performance status, haemoglobin and liver function) were explored to be related to FN by logistic regression.

Results

The neutrophil time course following docetaxel treatment was well described by the model. EC50 and MTT were both significantly related to the probability of developing FN where low parameter values result in a rapid decline, low nadir and an increased risk of FN. None of the evaluated risk factors or myelosuppression descriptors were significant.

Conclusion

The probability to develop FN in patients who experience grade IV neutropenia was dependent on the myelosuppression time profile. Patients with a rapid neutrophil decline and high drug sensitivity had a higher probability to develop FN. Model-based parameter estimates were superior predictors over descriptive values such as the nadir or duration of neutropenia.
Literatur
1.
Zurück zum Zitat Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia—risks, consequences, and new directions for its management. Cancer 100(2):228–237PubMedCrossRef Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia—risks, consequences, and new directions for its management. Cancer 100(2):228–237PubMedCrossRef
3.
Zurück zum Zitat Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266PubMedCrossRef Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266PubMedCrossRef
4.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JAH, Wingard JR (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427–431PubMedCrossRef Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JAH, Wingard JR (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427–431PubMedCrossRef
5.
Zurück zum Zitat Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32PubMedCrossRef Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32PubMedCrossRef
6.
Zurück zum Zitat Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P (2005) 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. Br Med J 330(7485):217–220CrossRef Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P (2005) 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. Br Med J 330(7485):217–220CrossRef
7.
Zurück zum Zitat Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei E (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90(16):1205–1211PubMedCrossRef Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei E (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90(16):1205–1211PubMedCrossRef
8.
Zurück zum Zitat Mayers C, Panzarella T, Tannock IF (2001) Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91(12):2246–2257PubMedCrossRef Mayers C, Panzarella T, Tannock IF (2001) Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91(12):2246–2257PubMedCrossRef
9.
Zurück zum Zitat Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80(11):1763–1766PubMedCrossRef Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80(11):1763–1766PubMedCrossRef
10.
Zurück zum Zitat Cameron DA, Massie C, Kerr G, Leonard RCF (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89(10):1837–1842PubMedCrossRef Cameron DA, Massie C, Kerr G, Leonard RCF (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89(10):1837–1842PubMedCrossRef
11.
Zurück zum Zitat Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75(2):301–305PubMedCrossRef Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75(2):301–305PubMedCrossRef
12.
Zurück zum Zitat Pascoe J, Cullen M (2006) The prevention of febrile neutropenia. Curr Opin Oncol 18(4):325–329PubMedCrossRef Pascoe J, Cullen M (2006) The prevention of febrile neutropenia. Curr Opin Oncol 18(4):325–329PubMedCrossRef
13.
Zurück zum Zitat Timmer-Bonte JNH, Tjan-Heijnen VCG (2006) Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors. Anticancer Drugs 17(8):881–889PubMedCrossRef Timmer-Bonte JNH, Tjan-Heijnen VCG (2006) Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors. Anticancer Drugs 17(8):881–889PubMedCrossRef
14.
Zurück zum Zitat Wingard JR, Elmongy M (2009) Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics. Crit Rev Oncol Hematol 72(2):144–154PubMedCrossRef Wingard JR, Elmongy M (2009) Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics. Crit Rev Oncol Hematol 72(2):144–154PubMedCrossRef
15.
Zurück zum Zitat Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187–3205PubMedCrossRef Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187–3205PubMedCrossRef
16.
Zurück zum Zitat Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10(6):427–437PubMedCrossRef Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10(6):427–437PubMedCrossRef
17.
Zurück zum Zitat Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, Dale DC (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117(9):1917–1927. doi:10.1002/cncr.25691 PubMedCrossRef Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, Dale DC (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117(9):1917–1927. doi:10.​1002/​cncr.​25691 PubMedCrossRef
18.
Zurück zum Zitat Bodey GP, Buckley M, Sathe YS, Freireic EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64(2):328–340PubMed Bodey GP, Buckley M, Sathe YS, Freireic EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64(2):328–340PubMed
19.
Zurück zum Zitat Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20(24):4713–4721PubMedCrossRef Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20(24):4713–4721PubMedCrossRef
20.
Zurück zum Zitat Sandstrom M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO (2005) Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 23(3):413–421PubMedCrossRef Sandstrom M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO (2005) Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 23(3):413–421PubMedCrossRef
21.
Zurück zum Zitat Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO (2006) Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 58(2):143–156PubMedCrossRef Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO (2006) Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 58(2):143–156PubMedCrossRef
22.
Zurück zum Zitat Troconiz IF, Garrido MJ, Segura C, Cendros JM, Principe P, Peraire C, Obach R (2006) Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother Pharmacol 57(6):727–735PubMedCrossRef Troconiz IF, Garrido MJ, Segura C, Cendros JM, Principe P, Peraire C, Obach R (2006) Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother Pharmacol 57(6):727–735PubMedCrossRef
23.
Zurück zum Zitat Leger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, Chatelut E (2004) Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76(6):567–578PubMedCrossRef Leger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, Chatelut E (2004) Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76(6):567–578PubMedCrossRef
24.
Zurück zum Zitat Latz J, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD (2006) A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57(4):412–426PubMedCrossRef Latz J, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD (2006) A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57(4):412–426PubMedCrossRef
25.
Zurück zum Zitat Hansson EK, Wallin JE, Lindman H, Sandstrom M, Karlsson MO, Friberg LE (2010) Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol 65(5):839–848PubMedCrossRef Hansson EK, Wallin JE, Lindman H, Sandstrom M, Karlsson MO, Friberg LE (2010) Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol 65(5):839–848PubMedCrossRef
26.
Zurück zum Zitat Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO (2006) Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 12(18):5481–5490PubMedCrossRef Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO (2006) Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 12(18):5481–5490PubMedCrossRef
27.
Zurück zum Zitat O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812–2823PubMedCrossRef O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812–2823PubMedCrossRef
28.
Zurück zum Zitat Beal S, Sheiner L, Boekmann A, Bauer RJ (2009) NONMEM user’s guides (1989–2006). Icon Development Solutions, Ellicott City Beal S, Sheiner L, Boekmann A, Bauer RJ (2009) NONMEM user’s guides (1989–2006). Icon Development Solutions, Ellicott City
29.
Zurück zum Zitat Lindbom L, Ribbing J, Jonsson EN (2004) Perls-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75(2):85–94PubMedCrossRef Lindbom L, Ribbing J, Jonsson EN (2004) Perls-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75(2):85–94PubMedCrossRef
30.
Zurück zum Zitat Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 80(3):241–257CrossRef Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 80(3):241–257CrossRef
31.
Zurück zum Zitat Jonsson EN, Karlsson MO (1999) Xpose:an Splus based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51–64PubMedCrossRef Jonsson EN, Karlsson MO (1999) Xpose:an Splus based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51–64PubMedCrossRef
32.
Zurück zum Zitat Bruno R, Vivier N, Vergniol JC, DePhillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere(R)): model building and validation. J Pharmacokinet Biopharm 24(2):153–172PubMedCrossRef Bruno R, Vivier N, Vergniol JC, DePhillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere(R)): model building and validation. J Pharmacokinet Biopharm 24(2):153–172PubMedCrossRef
33.
Zurück zum Zitat Karlsson MO, Port RE, Ratain MJ, Sheiner LB (1995) A population-model for the leukopenic effect of etoposide. Clin Pharmacol Ther 55(2):325–335CrossRef Karlsson MO, Port RE, Ratain MJ, Sheiner LB (1995) A population-model for the leukopenic effect of etoposide. Clin Pharmacol Ther 55(2):325–335CrossRef
34.
Zurück zum Zitat Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ (2000) Models of schedule dependent haematological toxicity of 2’-deoxy-2’-methylidenecytidine (DMDC). Eur J Clin Pharmacol 56(8):567–574PubMedCrossRef Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ (2000) Models of schedule dependent haematological toxicity of 2’-deoxy-2’-methylidenecytidine (DMDC). Eur J Clin Pharmacol 56(8):567–574PubMedCrossRef
35.
Zurück zum Zitat Cartwright GE, Athens JW, Wintrobe MM (1964) The kinetics of granulopoiesis in normal man. Blood 24(6):780–803PubMed Cartwright GE, Athens JW, Wintrobe MM (1964) The kinetics of granulopoiesis in normal man. Blood 24(6):780–803PubMed
37.
Zurück zum Zitat Zhang L, Beal SL, Sheiner LB (2003) Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 30(6):387–404PubMedCrossRef Zhang L, Beal SL, Sheiner LB (2003) Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 30(6):387–404PubMedCrossRef
39.
Zurück zum Zitat Bruno R, Hille D, Riva A, Vivier N, Huinnink W, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravclin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16(1):187–196PubMed Bruno R, Hille D, Riva A, Vivier N, Huinnink W, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravclin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16(1):187–196PubMed
40.
Zurück zum Zitat Ozawa K, Minami H, Sato H (2008) Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients. Cancer Chemother Pharmacol 62(3):551–557PubMedCrossRef Ozawa K, Minami H, Sato H (2008) Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients. Cancer Chemother Pharmacol 62(3):551–557PubMedCrossRef
41.
Zurück zum Zitat Valero V (1997) Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol 24(4):S11–S18 Valero V (1997) Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol 24(4):S11–S18
42.
Zurück zum Zitat Lyman GH, Delgado DJ (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 98(11):2402–2409PubMedCrossRef Lyman GH, Delgado DJ (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 98(11):2402–2409PubMedCrossRef
43.
Zurück zum Zitat Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6(2):109–118PubMed Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6(2):109–118PubMed
44.
Zurück zum Zitat Puisset F, Alexandre J, Treluyer JM, Raoul V, Roche H, Goldwasser F, Chatelut E (2007) Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 97(3):290–296PubMedCrossRef Puisset F, Alexandre J, Treluyer JM, Raoul V, Roche H, Goldwasser F, Chatelut E (2007) Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 97(3):290–296PubMedCrossRef
45.
Zurück zum Zitat Wallin J, Friberg LE, Karlsson MO (2010) Model-based neutrophil guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. Basic Clin Pharmacol Toxicol 106(3):234–242PubMedCrossRef Wallin J, Friberg LE, Karlsson MO (2010) Model-based neutrophil guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. Basic Clin Pharmacol Toxicol 106(3):234–242PubMedCrossRef
46.
Zurück zum Zitat Wallin J, Friberg LE, Karlsson MO (2009) A tool for neutrophil guided dose adaptation in chemotherapy. Comput Methods Programs Biomed 93(13):283–291PubMedCrossRef Wallin J, Friberg LE, Karlsson MO (2009) A tool for neutrophil guided dose adaptation in chemotherapy. Comput Methods Programs Biomed 93(13):283–291PubMedCrossRef
Metadaten
Titel
The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia
verfasst von
Emma K. Hansson
Lena E. Friberg
Publikationsdatum
01.04.2012
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 4/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-011-1769-7

Weitere Artikel der Ausgabe 4/2012

Cancer Chemotherapy and Pharmacology 4/2012 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.